Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Very strange , even for ONC

<< Previous

Bullboard Posts

Next >>

Comment by CMHarring218431on Feb 26, 2024 2:42pm

160 Views

Post# 35899720

RE:RE:RE:Very strange , even for ONC

FWIW .The short interest is usually reported twice a month at the middle and end of month +/-. Going by that schedule and the 12 month history on ONCY....it should have appeared by 02/19, at the very latest.

<< Previous

Bullboard Posts

Next >>

Nvidia reports record revenue in Q3